ArticleInfection and drug resistance2018
High-dose amikacin for achieving serum target levels in critically ill elderly patients.
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.Frontiers in microbiology · 2025Pooled it
- Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations.European journal of hospital pharmacy : science and practice · 2023Pooled it
- Clinical Considerations of Amikacin Pharmacotherapy in Adults-A Narrative Review with Focus on Safety and TDM.Antibiotics (Basel, Switzerland) · 2026Review
- Nomograms for Therapeutic Drug Monitoring of High-Dose Amikacin in Critically Ill Patients: Insights from a Population Pharmacokinetic Analysis and Dosing Simulation.Clinical pharmacokinetics · 2026Article
- Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producingAntimicrobial agents and chemotherapy · 2026Article
- Therapeutic Drug Monitoring-Based Population Pharmacokinetics of Amikacin in Patients at a Teaching Hospital.Antibiotics (Basel, Switzerland) · 2025Article
- MarR-Dependent Transcriptional Regulation ofAntimicrobial agents and chemotherapy · 2023Article
- Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients.Antibiotics (Basel, Switzerland) · 2023Article
- Detection of subclinical nephrotoxicity induced by aminoglycosides in critically ill elderly patients using trough levels and urinary neutrophil gelatinase-associated lipocalin.European journal of hospital pharmacy : science and practice · 2022Article
- Evaluation of amikacin dosing schedule in critically ill elderly patients with different stages of renal dysfunction.European journal of hospital pharmacy : science and practice · 2022Article
- Evaluation of Current Amikacin Dosing Recommendations and Development of an Interactive Nomogram: The Role of Albumin.Pharmaceutics · 2021Article
- Optimized Extraction of Amikacin from Murine Whole Blood.Molecules (Basel, Switzerland) · 2021Article
- Evaluation of Amikacin Pharmacokinetics in Critically Ill Patients with Intra-abdominal Sepsis.Advanced pharmaceutical bulletin · 2020Article
- Is Holmium Laser Enucleation of the Prostate a Good Surgical Alternative in Benign Prostatic Hyperplasia Management? A Review Article.Journal of lasers in medical sciences · 2020Review
- Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents againstInfection and drug resistance · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo achieve target concentrations, the application of higher-than-standard doses of amikacin is proposed for the treatment of sepsis due to an increase in volume of distribution and clearance, but little data are available on aminoglycoside administration in critically ill elderly patients. PATIENTS AND
methodsForty critically ill elderly patients (aged over 65 years) who required amikacin therapy due to severe documented, or suspected gram-negative infections, were randomly assigned to two treatment groups. Group A (20 patients) received 15 mg/kg amikacin and Group B (20 patients) received 25 mg/kg amikacin per day as a single daily dose. All the patients were monitored for renal damage by the daily monitoring of serum creatinine. The amikacin peak (C
resultsData from 18 patients in Group A and 15 patients in Group B were finally analyzed. On Day 3, the amikacin mean C
conclusionOur results suggest that the optimum dose of amikacin should be determined for elderly critically ill patients. It seems that higher-than-standard doses of amikacin with more extended intervals might be more appropriate than standard once-daily dosing in the elderly critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.